Cargando…

Lysosomes in acute myeloid leukemia: potential therapeutic targets?

Lysosomes, since their discovery, have been primarily known for degrading cellular macromolecules. However, in recent studies, they have begun to emerge as crucial regulators of cell homeostasis. They are at the crossroads of catabolic and anabolic pathways and are intricately involved in cellular t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafiq, Sreoshee, McKenna, Sharon L., Muller, Sylviane, Tschan, Mario P., Humbert, Magali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478647/
https://www.ncbi.nlm.nih.gov/pubmed/34462526
http://dx.doi.org/10.1038/s41375-021-01388-x
_version_ 1784576108564316160
author Rafiq, Sreoshee
McKenna, Sharon L.
Muller, Sylviane
Tschan, Mario P.
Humbert, Magali
author_facet Rafiq, Sreoshee
McKenna, Sharon L.
Muller, Sylviane
Tschan, Mario P.
Humbert, Magali
author_sort Rafiq, Sreoshee
collection PubMed
description Lysosomes, since their discovery, have been primarily known for degrading cellular macromolecules. However, in recent studies, they have begun to emerge as crucial regulators of cell homeostasis. They are at the crossroads of catabolic and anabolic pathways and are intricately involved in cellular trafficking, nutrient signaling, energy metabolism, and immune regulation. Their involvement in such essential cellular functions has renewed clinical interest in targeting the lysosome as a novel way to treat disease, particularly cancer. Acute myeloid leukemia (AML) is an aggressive blood cancer with a low survival probability, particularly in older patients. The genomic landscape of AML has been extensively characterized but few targeted therapies (with the exception of differentiation therapy) can achieve a long-term cure. Therefore, there is an unmet need for less intensive and more tolerable therapeutic interventions. In this review, we will give an overview on the myriad of functions performed by lysosomes and their importance in malignant disease. Furthermore, we will discuss their relevance in hematopoietic cells and different ways to potentially target them in AML.
format Online
Article
Text
id pubmed-8478647
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84786472021-10-08 Lysosomes in acute myeloid leukemia: potential therapeutic targets? Rafiq, Sreoshee McKenna, Sharon L. Muller, Sylviane Tschan, Mario P. Humbert, Magali Leukemia Review Article Lysosomes, since their discovery, have been primarily known for degrading cellular macromolecules. However, in recent studies, they have begun to emerge as crucial regulators of cell homeostasis. They are at the crossroads of catabolic and anabolic pathways and are intricately involved in cellular trafficking, nutrient signaling, energy metabolism, and immune regulation. Their involvement in such essential cellular functions has renewed clinical interest in targeting the lysosome as a novel way to treat disease, particularly cancer. Acute myeloid leukemia (AML) is an aggressive blood cancer with a low survival probability, particularly in older patients. The genomic landscape of AML has been extensively characterized but few targeted therapies (with the exception of differentiation therapy) can achieve a long-term cure. Therefore, there is an unmet need for less intensive and more tolerable therapeutic interventions. In this review, we will give an overview on the myriad of functions performed by lysosomes and their importance in malignant disease. Furthermore, we will discuss their relevance in hematopoietic cells and different ways to potentially target them in AML. Nature Publishing Group UK 2021-08-30 2021 /pmc/articles/PMC8478647/ /pubmed/34462526 http://dx.doi.org/10.1038/s41375-021-01388-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Rafiq, Sreoshee
McKenna, Sharon L.
Muller, Sylviane
Tschan, Mario P.
Humbert, Magali
Lysosomes in acute myeloid leukemia: potential therapeutic targets?
title Lysosomes in acute myeloid leukemia: potential therapeutic targets?
title_full Lysosomes in acute myeloid leukemia: potential therapeutic targets?
title_fullStr Lysosomes in acute myeloid leukemia: potential therapeutic targets?
title_full_unstemmed Lysosomes in acute myeloid leukemia: potential therapeutic targets?
title_short Lysosomes in acute myeloid leukemia: potential therapeutic targets?
title_sort lysosomes in acute myeloid leukemia: potential therapeutic targets?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478647/
https://www.ncbi.nlm.nih.gov/pubmed/34462526
http://dx.doi.org/10.1038/s41375-021-01388-x
work_keys_str_mv AT rafiqsreoshee lysosomesinacutemyeloidleukemiapotentialtherapeutictargets
AT mckennasharonl lysosomesinacutemyeloidleukemiapotentialtherapeutictargets
AT mullersylviane lysosomesinacutemyeloidleukemiapotentialtherapeutictargets
AT tschanmariop lysosomesinacutemyeloidleukemiapotentialtherapeutictargets
AT humbertmagali lysosomesinacutemyeloidleukemiapotentialtherapeutictargets